For the quarter ending 2025-09-30, GANX made $4,863,851 in revenue. -$5,284,373 in net income. Net profit margin of -108.65%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development | 2,849,510 | 2,758,973 | 1,865,852.5 | 2,621,722 |
| General and administrative | 1,936,267 | 2,330,553 | 1,988,549.5 | 1,837,242 |
| Total operating expenses | 4,785,777 | 5,089,526 | 3,854,402 | 4,458,964 |
| Loss from operations | -4,785,777 | -5,089,526 | -3,854,402 | -4,458,964 |
| Interest income (expense), net | - | - | - | 105,405 |
| Interest income, net | 78,074 | 42,568 | 89,274 | - |
| Foreign exchange (loss) gain, net | -27,382 | -620,924 | 141,917.5 | -121,139 |
| Loss before income tax | -4,735,085 | -5,667,882 | -3,628,904.5 | -4,474,698 |
| Income tax | 549,288 | 141,205 | 262,306 | 10,994 |
| Net loss | -5,284,373 | -5,809,087 | -3,891,210.5 | -4,485,692 |
| Earnings per share, basic | -0.15 | -0.19 | -0.15 | -0.17 |
| Earnings per share, diluted | -0.15 | -0.19 | -0.15 | -0.17 |
| Weighted average number of shares outstanding, basic | 34,998,060 | 30,341,523 | -11,432,957 | 26,531,747 |
| Weighted average number of shares outstanding, diluted | 34,998,060 | 30,341,523 | -11,432,957 | 26,531,747 |
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)